Hillmark is an innovative company that enables rapid and efficient design of novel and better drugs to benefit patients. We leverage AI-driven in-silico methods to accelerate the discovery of superior lead candidates in a time and cost  efficient manner. In contrast to classical drug discovery and design, relying on expensive high throughput technology and the physical availability of costly compound libraries, in-silico screening bypasses the need for large-scale in vitro testing, and gives access to a much greater chemical space.

​​

“Together, we can go far.”

​

Based on over 15 years’ experience with successful collaborations, we help R&D teams to find new and better drugs. We have a track record identifying molecules across a wide range of different diseases, and discovered new ways to diagnose illnesses.
 

We offer our AI computing pipelines to help research teams find and test new drugs faster, cheaper, greener and faster than the classical drug discovery and design methods.